SynthesisDrug and alcohol dependence2014
Changes in quality of life (WHOQOL-BREF) and addiction severity index (ASI) among participants in opioid substitution treatment (OST) in low and middle income countries: an international systematic review.
Synthesis in Drug and alcohol dependence, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 4 syntheses or guidelines pooled it, 113 citations in OpenAlex.
- Medication for opioid use disorder in the Arab World: A systematic review.The International journal on drug policy · 2022Pooled it
- Interim opioid agonist treatment for opioid addiction: a systematic review.Harm reduction journal · 2022Pooled it
- Global patterns of opioid use and dependence: harms to populations, interventions, and future action.Lancet (London, England) · 2019Pooled it
- Measuring quality of life in opioid-dependent people: a systematic review of assessment instruments.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2017Pooled it
- Opioid consumption frequency and its associations with potential life problems during opioid agonist treatment in individuals with prescription-type opioid use disorder: exploratory results from the OPTIMA Study.Harm reduction journal · 2025Trial
- Sleep disorders as a prospective intervention target to prevent drug relapse.Frontiers in public health · 2022Trial
- Psychiatric symptoms, quality of life, and HIV status among people using opioids in Saint Petersburg, Russia.Drug and alcohol dependence · 2017Trial
- Safety of a Rapidly Dissolving Buprenorphine/Naloxone Sublingual Tablet (BNX-RDT) for Treatment of Opioid Dependence: A Multicenter, Open-label Extension Study.Journal of addiction medicineTrial
- Cannabis Use Among Individuals Treated with Medication for Opioid Use Disorder: Correlates, Patterns, and Motivations for Use.Substance use & addiction journal · 2026Article
- Examining quality of life by recovery status among college students with a history of substance use.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Medical Cannabis and Psychological Well-Being in Illinois' Opioid Alternative Pilot Program.American journal of preventive medicine · 2025Article
- Comparing quality of life methadone and buprenorphine for opioid substitution treatment in Iran.Scientific reports · 2025Article
- A prospective study of the impact of an emotional intelligence program on opioid relapse and its determinants in upper Egypt.BMC psychology · 2025Article
- Quality of life whilst ageing in opioid agonist treatment: a narrative analysis.BMC public health · 2025Article
- Psychometric performance of tools to measure internalized drug use stigma among people who use drugs and people on medication-assisted treatment in Dar es Salaam, Tanzania.Drug and alcohol dependence · 2024Article
- Are the self-stigma and perceived stigma of patients treated with methadone or buprenorphine still a problem fifty years after the marketing authorization for opioid agonist treatment? The observational STIGMA study.Addiction science & clinical practice · 2024Observational
- Article
- Medication adherence and quality of life among geriatric patients: Insights from a hospital-based cross-sectional study in India.PloS one · 2024Article
- Navigating Adherence: Unraveling Factors Shaping Opioid Substitution Therapy Compliance.Cureus · 2024Article
- Health-related quality of life among people who inject drugs in Australia.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundOpioid substitution treatment (OST) can increase quality of life (WHOQOL-BREF) and reduce addiction severity index (ASI) scores among participants over time. OST program participants have noted that improvement in quality of life is one of the most important variables to their reduction in drug use. However, there is little systematic understanding of WHOQOL-BREF and ASI domain changes among OST participants in low and middle-income countries (LMIC).
methodsUtilizing PRISMA guidelines we conducted a systematic literature search to identify OST program studies documenting changes in WHOQOL-BREF or ASI domains for participants in buprenorphine or methadone programs in LMIC. Standardized mean differences for baseline and follow-up domain scores were compared along with relationships between domain scores, OST dosage, and length of follow-up.
resultsThere were 13 OST program studies with 1801 participants from five countries eligible for inclusion in the review. Overall, statistically significant changes were noted in all four WHOQOL-BREF domain and four of the seven ASI domain scores (drug, psychological, legal, and family) documented in studies. Dosage of pharmacologic medication and length of follow-up did not affect changes in domain scores.
conclusionWHOQOL-BREF and ASI domain scoring is a useful tool in measuring overall quality of life and levels of addiction among OST participants. Coupled with measurements of blood-borne infection, drug use, relapse, and overdose, WHOQOL-BREF and ASI represent equally important tools for evaluating the effects of OST over time and should be further developed as integrated tools in the evaluation of participants in LMIC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.